Resolvins: A New Paradigm for Mucosal Healing
First-in-class, Resolvin-based therapies
enabled by HEALER technology platform.
TP-317: Thetis’ lead candidate, TP-317, is a potential first-in-class, safe, oral therapy targeted at inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease. TP-317 is a new molecular entity (NME) that delivers Resolvin E1 (RvE1), an endogenous lipid mediator that resolves inflammation and promotes mucosal healing without compromising immune function. In preclinical studies, TP-317 has been shown to modulate inflammatory processes associated with IBD pathogenesis including immune cell infiltration, proinflammatory cytokine expression and maintenance of epithelial barrier integrity. Based on its anticipated product profile, Thetis proposes to investigate TP-317 as oral treatment for induction and maintenance of remission in IBD patients failing first-line 5-ASA therapy, an unaddressed segment with limited therapeutic options beyond escalating to potent immunosuppressive therapies.
Thetis was recently awarded a $2.3 million Fast Track NIH grant supporting TP-317 development and is targeting initial clinical studies in 2020.
TP-417: TP-417 is an NME that delivers Resolvin D1 (RvD1), an endogenous metabolite of docosahexaenoic acid. RvD1 has demonstrated efficacy in multiple immunological and inflammatory disease models, including psoriasis, dermatitis, wound healing, arthritis, multiple sclerosis, and pulmonary inflammation. Thetis is currently evaluating potential indications for TP-417.